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Abstract
Background: The prediction of response to treatment would be valuable for managing cervical
carcinoma with neoadjuvant chemotherapy.
Methods: To this end, the expression of VEGF was analyzed by immunohistochemistry using
paraffin-embedded pre-treatment cervical biopsy tissues. This study included 29 patients with bulky
IB to IIA cervical squamous cell carcinoma treated with neoadjuvant chemotherapy.
Results: Fifteen (51.7%) of 29 patients were scored as VEGF-positive. Response to chemotherapy
(complete response or residual tumor with less than 3 mm stromal invasion) was observed in eight
patients (27.6%), and it was negatively associated with VEGF expression (P = 0.009). With logistic
regression analysis, VEGF positivity continued to be an independent predictor for poor response
(P = 0.032). In addition, the progression-free survival rate was significantly lower in patients with
VEGF-positive tumors (P = 0.033).
Conclusion: Pretreatment assessment of VEGF expression may provide additional information for
identification of patients with cervical cancer who had a low likelihood of response to neoadjuvant
chemotherapy and an unfavorable prognosis.
Background
Carcinoma of the uterine cervix is the second most com-
mon cancer in women, but the prognosis remains very
poor in bulky or locally advanced disease [1]. Although
concurrent chemoradiation (CCRT) is now considered
standard treatment, neoadjuvant chemotherapy (NAC)
has been adopted to improve the prognosis for these cases
[2,3]. The development of convenient and reliable
biomarkers predicting the treatment response would be
valuable for patient management. If non-responsive
tumors could be identified before NAC, using predictive
biological factors, these patients could be allocated to
CCRT. Furthermore, it would be reinforced if the biologi-
cal factors found do not affect the response to CCRT.
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The correlation of angiogenesis with either metastasis or a
poor prognosis has been reported in various cancers [4-6].
Among the angiogenic factors, vascular endothelial
growth factor (VEGF) has been shown to have a pivotal
role in tumor angiogenesis. However, the correlation
between VEGF expression and prognosis in patient with
cervical cancer has been inconsistent; this may be because
of the marked heterogeneity of patient disease stages and
treatment modalities in reported studies [7-9]. Although,
there are some reports that show that VEGF plays an
important role in patient response to chemotherapeutic
agents, [10] there is little information available on its pre-
dictive value for treatment response in patients receiving
NAC for cervical carcinoma. Therefore, we evaluated
whether VEGF may have predictive value for patient
response to NAC in cases with bulky cervical carcinoma.
The aim of the present study was to investigate the expres-
sion of VEGF and their possible role as predictors of
response to NAC in patients with bulky cervical carci-
noma.
Methods
Patients and samples
Of the patients with locally advanced cervical carcinoma,
who had presented to the Samsung Medical Center, 46
patients with stage IB2 to IIB enrolled into a phase II trial
of NAC [11]. Among them, 29 patients with stage IB2 to
IIA and squamous cell histology were selected to mini-
mize heterogeneity of the patient population studied (15
patients with stage IIB and 2 patients with adenocarci-
noma were excluded). The Institutional Review Board at
Samsung Medical Center (Seoul, Korea) approved the
protocol, and all patients provided written informed con-
sent before entry into the trial. None of the patients was
pretreated with any other chemotherapy or radiotherapy
before the NAC. The median patient age was 47 years
(range, 33 to 70). Twenty (69.0%) patients had stage IB2
disease and nine (31.0%) patients had stage IIA. The other
clinicopathologic characteristics are shown in Table 1.
Treatment and response
Cisplatin-based chemotherapy (combination of vincris-
tine 1 mg/m2, mitomycin-C 10 mg/m2 and cisplatin 75
mg/m2) was administered every 3 weeks [11]. A type III
radical hysterectomy with pelvic and paraaortic lymph
node dissection was performed within 3 weeks of the
administration of the third cycle of NAC in all patients.
Following radical surgery, adjuvant radiotherapy was per-
formed if lymph node metastasis, parametrial involve-
ment or a positive resection margin were found.
In this study, the tumor response was evaluated patholog-
ically. Complete response (CR) was defined as a complete
disappearance of the invasive tumor in the cervix with
negative nodes, and optimal pathologic response (OPR)
was defined as a residual tumor with less than 3 mm stro-
mal invasion. The 3-mm threshold used was chosen
because it represents the maximal extension of FIGO stage
IA1 cervical tumor, which is usually considered cured after
local resection. And the role of OPR as a possible surro-
gate endpoint for survival in the neoadjuvant setting, has
been reported [12]. In the present study, patients with CR
or OPR were grouped together as responders.
Table 1: Immunoreactivity of VEGF according to clinicopathologic characteristics of the cervical carcinoma patients
No. of patients VEGF expression
Variables Positive Negative P
Total 29 15 14
Age
≥50 years 12 7 5 0.55
< 50 years 17 8 9
Stage
IB2 20 9 11 0.28
IIA 9 6 3
Cervical tumor size
≥5 cm 14 9 5 0.19
< 5 cm 15 6 9
Clinical node involvement
Yes 11 7 4 0.32
No 18 8 10
SCC Ag level
≥5 ng/ml 14 8 6 0.57
< 5 ng/ml 15 7 8
a(n = 29)
aThe P-value was determined using Chi-square test or Fisher's exact test.BMC Cancer 2008, 8:295 http://www.biomedcentral.com/1471-2407/8/295
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Immunohistochemistry and evaluation
Paraffin-embedded tissue blocks of formalin-fixed cervi-
cal biopsy specimens taken pre-treatment, were processed
for conventional histological assessment by hematoxylin
and eosin (H&E) staining and immunohistochemical
(IHC) analysis using the avidin – biotin – peroxidase
method. VEGF protein expression was detected by mouse
anti-human monoclonal VEGF (ab1316) antibody
(Abcam, Inc., Cambridge, UK), using conventional perox-
idase methods [13]. In brief, 4 μm thick sections were
deparaffinized in xylene, dehydrated through graded alco-
hol concentrations and incubated in citrate buffer (pH =
6.0) for 5 min using a household microwave oven at 800
W. After microwave exposure, the slides were allowed to
cool to room temperature. The slides were briefly washed
with PBS and incubated for 15 min with 3% hydrogen
peroxide in methanol to block endogenous peroxidase
activity. The antibody to VEGF was diluted 1:100 and
incubated for 1 h at room temperature. Biotinylated anti-
mouse/rabbit antibodies (DAKO) at a dilution of 1:500
were used as the second antibody. Negative controls
included substitution of the monoclonal antibody with
normal mouse IgG of the same concentration as the mon-
oclonal antibody [see Additional file 1]. Sections of cor-
pus luteum were used as positive control for VEGF
immunostaining. After washing, ABC (DAKO) was
applied and diaminobenzydine was used for visualiza-
tion. Tissue sections were lightly counterstained with
hematoxylin and then examined by light microscopy.
Assessment of the staining was scored independently by
two investigators (SYS and CHC) without knowledge of
the clinicopathological findings. Expression was defined
as positive if distinct staining of the cytoplasm was
observed in at least 10% of tumor cells [14]. The scoring
by the two investigators was similar. In the cases of disa-
greement, slides were reevaluated and discussed until con-
sensus was achieved.
Statistical analysis
Fisher's exact probability test or the Chi-square test was
used to analyze frequency data. Multiple logistic regres-
sion models were used to identify independent prognostic
factors for patient response. The tumor stage, nodal
involvement, tumor size, and SCC-Ag levels were entered
into the logistic regression models. Disease-free survival
was measured by the Kaplan-Meier method. Differences
between groups were tested using the log-rank test. To
determine the independent prognostic value for patient
disease-free survival, a Cox regression model was con-
structed using tumor stage, LN involvement, tumor size,
SCC-Ag level, and IHC status as covariates. A P-value of
less than 0.05 was considered significant. SPSS 10.0 (SPSS
Inc., Chicago, IL) was used for the statistical analysis.
Results
Figure 1 show representative results of IHC staining. Fif-
teen (51.7%) of 29 patients were scored as VEGF-positive
(Table 1). Table 1 lists the positivity of the proteins
according to clinicopathologic characteristics.
Pathologic responses, including complete and optimal
responses, were observed in eight (27.6%) patients, with
no response in the remaining 21 (72.4%) patients (Table
2). VEGF expression was shown to be highly associated
with tumor susceptibility to NAC. The response rate of
VEGF-positive tumors was significantly lower than VEGF-
negative tumors (7% vs. 50%, P = 0.009). When logistic
regression was applied, VEGF positivity continued to be
an independent predictor of poor response to treatment
(P = 0.032).
With a median follow-up period of 48 months (range, 3
to 105), three (10.3%) of 29 patients died of disease and
recurrence occurred in seven (24.1%). The overall 5-year
disease-free survival rate was higher in the responder
group than the non-responder group (100% vs.  65%),
although this difference was not statistically significant (P
= 0.07) (Figure 2A). The progression-free survival rate was
significantly lower in patients with VEGF-positive tumors
(vs. VEGF-negative tumors, P = 0.033) (Table 3 and Figure
2B). VEGF-positivity was identified as an independent
predictor of patient disease-free survival using a Cox
regression model (P = 0.037; hazards ratio, 11.4; 95% CI,
1.15 – 112.58) (Table 3).
Discussion
In this study, the clinical significance of IHC-positivity for
VEGF in pre-treatment biopsy specimens was examined in
29 patients with cervical squamous cell carcinoma under-
going NAC. The most interesting finding of our study was
the strong correlation between VEGF expression and
response to NAC. These results suggest that patients with
cervical cancer who are positive for VEGF expression are
less likely to benefit from NAC. Therefore, patient moni-
toring for VEGF expression may provide an important
determinant for the differential treatment of bulky cervi-
cal cancer. Although it is very difficult to develop the best
alternative strategy in such VEGF-positive patients, con-
current chemoradiation or radical surgery without delay
or the addition of anti-VEGF therapy may be useful in
improving the prognosis of those patients [15]. However,
additional study is needed for confirmation of these find-
ings.
The reason for the correlation between VEGF positivity
and chemoresistance is unclear. The presence of increased
vascularity may suggest improved tumor oxygenation and
drug delivery; this may improve response to chemother-
apy. However, this remains contradictory in many casesBMC Cancer 2008, 8:295 http://www.biomedcentral.com/1471-2407/8/295
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[16,17]. Unlike normal blood vessels, tumor vessels are
structurally and functionally abnormal, i.e., the formation
of tortuous and saccular blood vessels that are poorly
organized and hyperpermeable [18]. These abnormalities
can increase resistance to blood flow and impair blood
supply, and therefore compromise the delivery and effec-
tiveness of conventional cytotoxic therapies [19]. It has
also been suggested that the role of angiogenic factors in
the treatment response may be governed by hypoxia. Piret
and colleagues suggested that HIF-1α (key proteins regu-
lating angiogenesis) has both pro- and anti-apoptotic
effects [20]. Mild hypoxia causes the expression of various
anti-apoptotic proteins, whereas severe hypoxia leads to
cell death, at least in part, through stabilization of p53 by
HIF-1α [20]. The overall balance of the activation effects
of HIF-1α may depend on the type of cancer and treat-
ment modality used [21].
Clinical studies on the correlation between VEGF expres-
sion and prognosis have reported inconsistent results [7-
9,22]. Some reasons for the conflicting results include the
following. First, the patient groups studied were heteroge-
neous in terms of disease stages and treatment modalities.
Second, the studies were prone to sampling errors because
the neovascularization status of the tumor could not be
reliably determined with a single measurement of only a
small portion of the whole tumor. Jain reported that not
only does the microcirculation vary from one tumor to the
next, but within the same tumor, it varies both spatially
and temporally [23].
Conclusion
The present study showed that the assessment of VEGF
expression in pretreatment biopsy specimens could pro-
vide additional information to identify patients with a
Representative examples of VEGF staining in bulky cervical carcinoma showing cases with no staining (A), weak staining (B),  moderate staining (C) and strong staining (D) (×200) Figure 1
Representative examples of VEGF staining in bulky cervical carcinoma showing cases with no staining (A), 
weak staining (B), moderate staining (C) and strong staining (D) (×200).
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poor chance of response to NAC and unfavorable progno-
sis in patients with bulky cervical carcinoma.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CHC and SYS collected the data, performed analysis and
prepared the manuscript. JJC, YAP, HK and TJK performed
the immunoassays and statistical analysis. JWL, BGK and
JHL selected the cases and interpreted the results. DSB
designed the study concept, interpreted the results and
approved the final manuscript.
Table 2: Clinicopathologic parameters and the expression of VEGF as predictors of response to neoadjuvant chemotherapy in patients 
with bulky cervical carcinoma
Pathologic responder Nonresponder
Characteristics No. of patients RR CR (n = 4) OPR a (n = 4) (n = 21) Pb Pc
Age, years 0.16
Median 58 47 46
Range 38 – 60 34 – 60 33 – 70
Cervical tumor size (cm) 0.07 0.22
Median 3.8 3.5 5.0
Range 3.2 – 6.0 3.0 – 5.6 3.7 – 7.1
Clinical node involvement 0.98 0.22
Yes 11 27.3% 2 1 8
No 18 27.8% 2 3 13
Stage 0.67 0.54
IB2 20 30.0% 2 4 14
IIA 9 22.2% 2 0 7
SCC Ag level 0.47 0.36
≥5 ng/ml 14 21.4% 1 2 11
< 5 ng/ml 15 33.3% 3 2 10
VEGF expression 0.009 0.032
Negative 14 50.0% 3 4 7
Positive 15 6.7% 1 0 14
aResidual tumor but only with less than 3 mm stromal invasion
bRank sum test or Chi-square test/Fisher's exact test
cLogistic regression analysis with stage, tumor size, SCC-Ag level, and lymph node involvement as a covariate.
RR, pathologic response rate; CR, complete response; OPR, optimal pathologic response
Table 3: Univariate and multivariate analysis of clinicopathologic factors affecting disease-free survival rate
Univariate analysis Multivariate analysis
Characteristics No. of patients 5-y DFS (%) P Relative risk (95% CI) P
Cervical tumor size
≥5 cm 14 69.2 0.50 0.66 0.53a
< 5 cm 15 80.0 (0.18 – 2.42)
Clinical node involvement
Yes 11 70.6 0.49 2.30 0.39
No 18 81.8 (0.35 – 15.10)
Stage
IB2 20 73.3 0.83 0.67 0.64
IIA 9 77.8 (0.13 – 3.58)
SCC Ag level
≥5 ng/ml 14 69.2 0.50 1.03 0.45a
< 5 ng/ml 15 80.0 (0.95 – 1.12)
VEGF expression
Negative 14 92.3 0.033 11.40 0.037
Positive 15 60.0 (1.15 – 112.58)
a Treated as a continuous variable.BMC Cancer 2008, 8:295 http://www.biomedcentral.com/1471-2407/8/295
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Disease-free survival curve as a function of pathologic response (A) and immunoreactivity to VEGF (B) Figure 2
Disease-free survival curve as a function of pathologic response (A) and immunoreactivity to VEGF (B). The P-
values were determined using the log-rank test.
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Negative controls for VEGF staining. All slides show negative staining 
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